Physician profile
Evan Rosen
NPI 1013948959
$4,511.62
in general payments reported to CMS, 2019-2025
28 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $177 · 2021: $1,056 · 2022: $1,858 · 2023: $387 · 2024: $197 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $902.84 | 2019-2025 | |
| Procept Biorobotics Corporation | $894.00 | 2022 | |
| Abbvie INC. | $330.61 | 2019-2022 | |
| Cook Medical LLC | $281.12 | 2019 | |
| Boston Scientific Corporation | $261.45 | 2019-2023 | Lithovue |
| Urogen Pharma, INC. | $239.79 | 2021-2023 | Jelmyto |
| Astellas Pharma US INC | $202.07 | 2020-2022 | |
| Antares Pharma, INC. | $193.21 | 2021-2022 | |
| Neotract INC. | $191.54 | 2019 | |
| Merck Sharp & Dohme LLC | $126.35 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $124.31 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $88.69 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $74.46 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $70.77 | 2020-2023 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $66.41 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $53.84 | 2021 | |
| Medtronic, INC. | $49.18 | 2024 | Interstim |
| Pfizer INC. | $45.10 | 2021 | |
| Baxter Healthcare | $44.39 | 2022 | |
| Allergan, INC. | $42.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $42.50 | 2021 | |
| Coloplast Corp | $36.36 | 2022 | |
| Clarus Therapeutics INC. | $34.99 | 2021 | |
| Teleflex LLC | $31.24 | 2021 | |
| Ferring Pharmaceuticals INC. | $26.63 | 2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $20.67 | 2022 | |
| Profound Medical Corp. | $18.48 | 2021 | |
| Metuchen Pharmaceuticals | $18.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.